[ad_1]
"Finasteride, used in the treatment of prostate hyperplasia, is extremely effective at reducing the risk of prostate cancer," revealed a study of the S-dubloi AG cancer research network.
Network researchers, an international group of clinical trials funded by the National Cancer Institute, published their findings in the latest issue of the New England Journal of Medicine.
The team studied the effectiveness of finasteride, used to treat the symptoms of prostate enlargement, thereby improving urinary flow and treating urinary tract problems.
The team conducted one of the largest clinical trials ever conducted on prostate cancer, involving more than 300,000 prostate cancer patients over the last two decades.
The results showed that finasteride had a lasting effect on people who took it to reduce the risk of prostate cancer compared to their placebo peers.
The researchers found that this drug reduces the risk of prostate cancer by 25%.
"Finasteride is safe, inexpensive and effective as a preventative strategy for prostate cancer," said Dr. Ian Thompson, head of the research team.
"Physicians should share these findings with men who undergo a prostate-specific antigen test to detect prostate cancer, and the drug will have a significant impact on this group of men," he said. said Thompson.
According to statistics from the World Health Organization, prostate cancer is the second most important cancer in men after lung cancer. It reached more than one million people worldwide in 2012 and more than 307,000 people died as a result of this disease.
[ad_2]
Source link
